Matsumoto, Kazuaki

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 薬効解析学講座 （Shiba-Kyoritsu）

Position

Professor
Page Top ▲

Career 【 Display / hide 】

  • 2003.04
    -
    2007.03

    鹿児島大学医学部・歯学部附属病院, 薬剤部, 医療職員

  • 2007.04
    -
    2014.03

    鹿児島大学医学部・歯学部附属病院, 薬剤部, 主任

  • 2014.04
    -
    2017.03

    慶應義塾大学薬学部, 実務薬学講座, 准教授

  • 2017.04
    -
    Present

    慶應義塾大学薬学部, 薬効解析学講座, 教授

Page Top ▲

Academic Background 【 Display / hide 】

  • 1994.04
    -
    1998.03

    Kumamoto University, 薬学部, 薬学科

    日本, University, Graduated

  • 1998.04
    -
    2000.03

    Kumamoto University, 薬学研究科

    日本, Graduate School, Completed, Master's course

  • 2000.04
    -
    2003.03

    Kumamoto University, 薬学研究科

    日本, Graduate School, Completed, Doctoral course

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（薬学）, Kumamoto University, Coursework, 2003.03

    α1-酸性糖蛋白質の生理作用と動態特性に関する研究

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 薬剤師免許証, 1998.07

  • 日本薬剤師研修センター認定薬剤師, 2006.03

  • 日本医療薬学会認定薬剤師, 2009.01

  • インフェクションコントロールドクター, 2009.01

  • 感染制御専門薬剤師, 2009.03

display all >>

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Medical pharmacy

Page Top ▲

Research Keywords 【 Display / hide 】

  • Drug Delivery System

  • 抗菌化学療法

  • 高齢者医療

Page Top ▲

Research Themes 【 Display / hide 】

  • 医薬品の薬効評価と副作用解析に基づいた薬物療法の最適化に関する研究, 

    2014.04
    -
    Present

Page Top ▲
 

Books 【 Display / hide 】

  • Clinical Practice Guideline for the Management of Invasive Candidiasis by the Japanese Society for Medical Mycology

    Kazuaki Matsumoto, 日本医真菌学会, 2021.08

  • 抗菌化学療法認定薬剤師テキスト改訂版

    松元一明, 日本化学療法学会, 2021.07

    Scope: 抗菌薬の治療薬物モニタリング,  Contact page： 41-50

  • 今日の治療指針2021

    松元一明, 医学書院, 2021.01

    Scope: 市中肺炎/急性中耳炎 服薬指導・薬剤情報

  • 今日の治療薬2021

    松元一明, 南江堂, 2021.01

  • 小児感染症治療ハンドブック2020-2021

    松元一明, 診断と治療社, 2020.12

    Scope: 小児科領域でTDMの対象となる薬剤／PK/PD

display all >>

Page Top ▲

Papers 【 Display / hide 】

  • Long-term pharmaceutical stability of liposome-encapsulated methemoglobin as an antidote for cyanide poisoning.

    Suzuki Y, Taguchi K, Kure T, Enoki Y, Otagiri M, Sakai H, Matsumoto K

    International journal of pharmaceutics （International Journal of Pharmaceutics)  610   121260 2021.11

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  0378-5173

    　View Summary

    Liposome-encapsulated methemoglobin (metHb@Lipo) has been developed as a novel antidote for cyanide poisoning. Antidotes for lethal acute poisoning should be capable of being easily stored as ready-to-use formulations without temperature restrictions. Here, we investigated the pharmaceutical stability of the metHb@Lipo suspension after one-year storage as a ready-to-use formulation at 4 °C, room temperature (23–28 °C) and 37 °C. The liposomal integrity of metHb@Lipo was observed after one year of storage at all storage temperatures with no physicochemical change or methemoglobin leakage outside the liposome. Furthermore, the encapsulated methemoglobin remained intact without aggregation, fragmentation, denaturation, or dissociation of heme. Fresh and stored metHb@Lipo were equivalent in their binding affinity against cyanide. Moreover, all one-year stored metHb@Lipo suspensions improved the mortality rates of lethal cyanide poisoning mice comparable to fresh metHb@Lipo suspension. Additionally, all stored metHb@Lipo suspensions preserved high biocompatibility, including blood compatibility and the lack of organ toxicity. In conclusion, the metHb@Lipo suspension was a pharmaceutically stable antidote for cyanide poisoning for at least one year without any temperature restrictions.

  • Impact of rifampicin on the pharmacokinetics of clarithromycin and 14-hydroxy clarithromycin in patients with multidrug combination therapy for pulmonary Mycobacterium avium complex infection.

    Iketani O, Komeya A, Enoki Y, Taguchi K, Uno S, Uwamino Y, Matsumoto K, Kizu J, Hasegawa N

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy （Journal of Infection and Chemotherapy)  28 （ 1 ） 61 - 66 2021.10

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  1341-321X

    　View Summary

    Introduction: Clarithromycin (CAM), ethambutol (EB), and rifampicin (RFP) combination therapy is used to treat pulmonary Mycobacterium avium complex (MAC) infection; however, serum CAM concentration decreases due to RFP-mediated induction of CYP3A activity. Therefore, we investigated the pharmacokinetics of CAM, 14-hydroxy clarithromycin (14-OH CAM), EB, and RFP in patients receiving this three-drug combination therapy. Methods: CAM monotherapy was started, EB was added 2 weeks later, and RFP was added 2 weeks after that. Serum CAM, 14-OH CAM, EB, and RFP concentrations were measured before and at 2, 4, 6, and 12 or 24 h after administration on days 14, 28, and 42, and pharmacokinetic parameters were calculated. Results: Median area under the curve (AUC) of CAM decreased by 92.1% from 0 to 12 h after concomitant administration of RFP compared with CAM monotherapy [1.7 (interquartile range [IQR], 1.4–1.8) μg·h/mL vs. 21.5 (IQR, 17.7–32.3) μg·h/mL, respectively]. In contrast, median AUC of 14-OH CAM was not significantly different between concomitant administration of RFP [9.1 (IQR, 7.9–10.9) μg·h/mL] and CAM monotherapy [8.2 (IQR, 6.3–9.3) μg·h/mL]. AUCs of CAM and 14-OH CAM did not change in CAM+EB combination therapy. Conclusions: When RFP is combined with CAM in the treatment of pulmonary MAC infection, the blood concentration of CAM significantly decreased and that of the active metabolite 14-OH CAM increased, but not significantly. Our results suggest that combination therapy with CAM and RFP needs to be reconsidered and may require dose modification in the treatment of pulmonary MAC infection.

  • Asymmetric Total Syntheses of Both Enantiomers of Plymuthipyranone B and Its Unnatural Analogues: Evaluation of anti-MRSA Activity and Its Chiral Discrimination.

    Moriyama M, Liu X, Enoki Y, Matsumoto K, Tanabe Y

    Pharmaceuticals (Basel, Switzerland) （Pharmaceuticals)  14 （ 9 ）  2021.09

    Research paper (scientific journal), Joint Work, Accepted

    　View Summary

    Chiral total syntheses of both enantiomers of the anti-MRSA active plymuthipyranone B and all of the both enantiomers of three unnatural and synthetic analogues were performed. These two pairs of four chiral compounds are composed of the same 3-acyl-5,6-dihydro-2H-pyran-2-one structure. The starting synthetic step utilized a privileged asymmetric Mukaiyama aldol addition using Ti(OiPr)4/(S)-BINOL or Ti(OiPr)4/(R)-BINOL catalysis to afford the corresponding (R)-and (S)-δ-hydroxy-β-ketoesters, respectively, with highly enantiomeric excess (> 98%). Conventional lactone formation and successive EDCI-mediated C-acylation produced the desired products, (R)-and (S)-plymuthipyranones B and three (R)-and (S)-synthetic analogues, with an overall yield of 42–56% with a highly enantiomeric excess (95–99%). A bioassay of the anti-MRSA activity against ATCC 43300 and 33591 revealed that (i) the MICs of the synthetic analogues against ATCC 43300 and ATCC 33591 were between 2 and 16 and 4 and 16 μg/mL, respectively, and those of vancomycin (reference) were 1 μg/mL. (ii) The natural (S)-plymuthipyranone B exhibited significantly higher activity than the unnatural (R)-antipode against both AACCs. (iii) The natural (R)-plymuthipyra-none B and (R)-undecyl synthetic analogue at the C6 position exhibited the highest activity. The present work is the first investigation of the SAR between chiral R and S forms of this chemical class.

  • Candidates for area under the time-concentration curve-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients.

    Hashimoto N, Kimura T, Hamada Y, Niwa T, Hanai Y, Chuma M, Fujii S, Matsumoto K, Shigemi A, Kawamura H, Takahashi Y, Takesue Y

    Journal of global antimicrobial resistance （Journal of Global Antimicrobial Resistance)  27   12 - 19 2021.08

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  2213-7165

    　View Summary

    Objectives:: Compared with vancomycin trough concentration (Cmin)-guided dosing, area under the concentration–time curve (AUC)-guided dosing is associated with decreased acute kidney injury (AKI). However, whether Cmin-guided or AUC-guided dosing should be used in patients other than those with serious MRSA infections remains uncertain. The purposes of this multicentre study were to identify risk factors for early- and late-phase vancomycin-induced AKI and to identify candidates for AUC-guided dosing, rather than Cmin-guided dosing, who require a more accurate dose titration to reduce the AKI risk. Methods:: A multivariate logistic regression analysis was applied to identify risk factors for AKI. Additionally, the cut‑off day for AKI onset, cut-off Cmin for AKI, safe Cmin for reduced AKI risk and probability of AKI were calculated. Results:: In total, 8.4% (159/1882) of patients developed AKI. AKI occurred within the first 7 days of therapy (early phase) in the vast majority of patients. Significant risk factors for AKI during the early phase were identified as Cmin > 20 mg/L, ICU stay, concurrent diuretic or piperacillin/tazobactam use, and pre-existing renal dysfunction. A temporarily elevated Cmin (>15–20 mg/L) was not associated with a greater risk of AKI. In patients with risk factors, the cut-off Cmin for AKI and the estimated safe Cmin for reduced AKI risk were 18.8–21.0 mg/L and <11.7–13.5 mg/L, respectively. Conclusion:: Patients with known AKI risk factors require a low target Cmin. The presence of several risk factors for AKI may indicate a need for more accurate dose titration using AUC-guided dosing.

  • Augmented clearance of nivolumab is associated with renal functions in chronic renal disease model rats.

    Taguchi K, Hayashi Y, Ohuchi M, Yamada H, Yagishita S, Enoki Y, Matsumoto K, Hamada A

    Drug metabolism and disposition: the biological fate of chemicals  2021.08

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  0090-9556

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • メトヘモグロビン内包リポソームの新規アジド中毒解毒剤としての有効性評価.

    羽生聡美, 鈴木悠斗, 田口和明, 久禮智子, 酒井宏水, 榎木裕紀, 小田切優樹, 松元一明

    第28回日本血液代替物学会年次大会 (日本血液代替物学会)  29 ( 1 ) 31 - 31 2021.09

    ISSN  1341-1594

  • 一酸化炭素結合型ヘモグロビン小胞体の急性呼吸窮迫症候群に対する有用性評価.

    渡部佑樹, 田口和明, 榎木裕紀, 酒井宏水, 小田切優樹, 松元一明

    第28回日本血液代替物学会年次大会 (日本血液代替物学会)  29 ( 1 ) 28 - 28 2021.09

    ISSN  1341-1594

  • メトヘモグロビン内包リポソームの長期安定性評価.

    鈴木悠斗, 田口和明, 久禮智子, 酒井宏水, 榎木裕紀, 小田切優樹, 松元一明

    第28回日本血液代替物学会年次大会 (日本血液代替物学会)  29 ( 1 ) 29 - 29 2021.09

    ISSN  1341-1594

  • 【難しい数式も、TDMもわからない!「ニガテさん」のための薬物動態】(第4章)患者背景によるADMEの変化に注目できる! 高齢者の薬物動態

    榎木 裕紀, 松元 一明

    調剤と情報 ((株)じほう)  27 ( 10 ) 1754 - 1761 2021.07

    Other article, Joint Work,  ISSN  1341-5212

  • 【肺炎をめぐるトピックス：基礎から臨床まで】バンコマイシンをめぐるPK/PD理論の新展開.

    松元 一明

    呼吸器内科 ((有)科学評論社)  39 ( 6 ) 544 - 548 2021.06

    Introduction and explanation (commerce magazine), Single Work,  ISSN  1884-2887

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • Mycobacterium abscessus complexに対するNacubactamとβラクタム薬の併用効果.

    三澤可奈, 西村知泰, 榎木裕紀, 田口和明, 宇野俊介, 上蓑義典, 松元一明, 長谷川直樹

    第70回日本感染症学会東日本地方会学術集会／第68回日本化学療法学会東日本支部総会合同学会 (東京都) , 2021.10, Oral Presentation(general)

  • リネゾリドによる血液毒性に与える腎障害またはトラフ値の影響.

    劉小茜, 長邑花, 榎木裕紀, 田口和明, 松元一明

    第70回日本感染症学会東日本地方会学術集会／第68回日本化学療法学会東日本支部総会合同学会 (東京都) , 2021.10, Oral Presentation(general)

  • シンポジウム17：エビデンス構築に基づいた抗菌薬TDMガイドライン2021「バンコマイシン」

    松元一明

    第70回日本感染症学会東日本地方会学術集会／第68回日本化学療法学会東日本支部総会合同学会 (東京都) , 2021.10, Symposium, Workshop, Panelist (nomination)

  • メトヘモグロビン内包リポソームの新規アジド中毒解毒剤としての有効性評価.

    羽生聡美, 鈴木悠斗, 田口和明, 久禮智子, 酒井宏水, 榎木裕紀, 小田切優樹, 松元一明

    第28回日本血液代替物学会年次大会 (東京都) , 2021.10, Oral Presentation(general)

  • メトヘモグロビン内包リポソームの長期安定性評価.

    鈴木悠斗, 田口和明, 久禮智子, 酒井宏水, 榎木裕紀, 小田切優樹, 松元一明

    第28回日本血液代替物学会年次大会 (東京都) , 2021.10, Oral Presentation(general)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • Investigation of the effectiveness of imeglimin as a potential therapeutic agent for sarcopenia

    2021.09
    -
    2023.08

    大日本住友製薬株式会社, 松元　一明, Commissioned ｒesearch, Principal Investigator

  • 肺Mycobacterium abscessus complex症に対するクロファジミンの有効性及び安全性を検討する医師主導治験実施のためのプロトコール作成研究

    2021.08
    -
    2022.03

    国立研究開発法人日本医療研究開発機構（AMED）, 革新的医療シーズ実用化研究事業, 南宮　湖, 松元　一明, Joint research, Co-investigator

  • MRSA骨感染症の克服を目指したテジゾリド最適化投与法の構築

    2021.04
    -
    2024.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 渡部　欣忍, 松元　一明, Grant-in-Aid for Scientific Research (C), Co-investigator

  • Hollow-Fiber Infection Modelを応用した新型コロナウイルス感染症（COVID-19）対する治療薬の開発促進に向けた評価法・検証法の構築に資する基盤研究

    2021.01
    -
    2022.03

    国立研究開発法人日本医療研究開発機構（AMED）, 新興・再興感染症に対する革新的医薬品等開発推進研究事業, 舘田　一博, 松元　一明, Joint research, Co-investigator

  • OP0595の臨床有効性評価

    2019.07
    -
    2021.12

    Meiji Seikaファルマ株式会社, 松元　一明, Commissioned ｒesearch, Principal Investigator

display all >>

Page Top ▲

Intellectual Property Rights, etc. 【 Display / hide 】

  • メトヘモグロビン小胞体を有効成分として含む医薬およびその使用

    Application No.： 特願2020-144044  2020.08 

    Patent, Joint, National application

Page Top ▲

Awards 【 Display / hide 】

  • 第31回日本医療薬学会年会 Young Investigator’s Award

    長邑花、榎木裕紀、田口和明、松元一明, 2021.10, 廃用性筋萎縮による敗血症病態増悪における骨格筋由来エクソソームの関与

    Country： 日本

  • MRSAフォーラム2020 一般演題優秀賞

    田代渉、北廣夕貴、森山大夢、濱村有那、高畑勇、川邊理奈、榎木裕紀、田口和明、松元一明, 2021.07, MRSA菌血症に対するダプトマイシンとバンコマイシンの有効性及び安全性の評価：システマティックレビュー＆メタ解析

    Country： 日本

  • MRSAフォーラム2020 一般演題優秀賞

    小島菜奈、筒浦萌子、森山大夢、水上雄貴、田代渉、長邑花、榎木裕紀、田口和明、竹末芳生、松元一明, 2021.07, バンコマイシンの有効性、安全性に関係するAUCとトラフ目標値、及びAUC ガイドとトラフガイドの比較に関するsystematic review、メタ解析

    Country： 日本

  • 2020 Top Reviewer Award for Biological and Pharmaceutical Bulletin (BPB)

    松元一明, 2021.05

    Country： 日本

  • 日本薬学会第141年会 口頭発表の部 学生優秀発表賞

    永井智也、榎木裕紀、中村秀明、田口和明、松元一明, 2021.03, 慢性腎臓病誘発サルコペニアに対するapelinの有用性評価

    Country： 日本

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • STUDY OF MAJOR FIELD (PHARMACODYNAMICS)

    2021

  • SEMINAR (PHARMACODYNAMICS)

    2021

  • RESEARCH FRONTIERS IN BIOMEDICAL SCIENCE

    2021

  • RESEARCH FOR BACHELOR'S THESIS 1

    2021

  • PRIOR LEARNING FOR CLINICAL PRACTICE 4

    2021

display all >>

Page Top ▲
 

Social Activities 【 Display / hide 】

Page Top ▲

Memberships in Academic Societies 【 Display / hide 】

  • 日本医真菌学会, 

    2019.02
    -
    Present

  • 日本DDS学会, 

    2018.05
    -
    Present

  • 日本臨床微生物学会, 

    2018.03
    -
    Present

  • 日本老年薬学会　理事・評議員, 

    2016.04
    -
    Present

  • 日本薬剤学会, 

    2015.12
    -
    Present

display all >>

Page Top ▲